8-K: Pulse Biosciences Reports Strong Cardiac Ablation Study Results

Pulse Biosciences announced positive late-breaking clinical study results for its nPulse Cardiac Surgical System in treating atrial fibrillation, demonstrating high success rates and safety.

Summary

• 44 patients have been treated by three investigators in the nPulse Cardiac Surgical System first-in-human feasibility study.
• In the initial cohort, 24 patients had ablation effectiveness and durability evaluated by electroanatomical mapping at approximately three months post-procedure.
• All (100%) posterior box isolations were acutely successful in the high-dose cohort.
• The success rate of Pulmonary Vein Isolation (PVI) was 94% (63/67 per vein) at approximately three months.
• Average total ablation time was 50 seconds with an average of 13 applications.
• No reports of esophageal or phrenic nerve damage were observed.
• No ablation-related severe or major adverse events were reported.

Sentiment

Score: 9

Explanation: The clinical study results are overwhelmingly positive, demonstrating high efficacy, safety, and speed for a novel technology in a significant medical field. This represents a strong validation of the nPulse Cardiac Surgical System's potential.

Positives

• 100% acute success for posterior box isolations in the high-dose cohort.
• High PVI success rate of 94% (63/67 per vein) at three months, indicating durable results.
• Rapid average total ablation time of 50 seconds with only 13 applications, suggesting efficient workflow.
• Demonstrated safety with no reports of esophageal or phrenic nerve damage, addressing a key concern in cardiac ablation.
• Absence of ablation-related severe or major adverse events.
• Pulse Biosciences is the first company to bring Pulsed Field Ablation (PFA) into the cardiac surgical field for atrial fibrillation.
• The nPulse Surgical Cardiac Clamp's efficient workflow has the potential to significantly expand the use of cardiac surgical ablation for patients suffering from atrial fibrillation.

Risks

• Early clinical successes may not be predictive of the safety and effectiveness of any medical device.
• Uncertainty regarding whether the nPulse Surgical Cardiac Clamp can safely and effectively create durable reproducible lesions.
• Uncertainty whether nPulse technology may offer significant advantages in safety, efficacy, and speed compared to traditional thermal ablation methods like radiofrequency.
• Risks associated with future clinical and regulatory initiatives anywhere in the world.
• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control.

Future Outlook

Pulse Biosciences remains on track to initiate an IDE study this year to clinically validate the nPulse Cardiac Surgical System and looks forward to continued collaboration with leading physicians as it works toward commercial approval and broader patient access.

Management Comments

• Dr. Bart van Putte, Cardiothoracic Surgeon at St. Antonius Hospital Nieuwegein, The Netherlands: "Electroanatomical mapping results for the first 24 patients treated with the nPulse Cardiac Surgical System show durable and consistent pulmonary vein isolation (PVI) and posterior box isolation, achieved safely with rapid ablation times."
• Dr. Bart van Putte: "This feasibility study represents the first use of an epicardial PFA surgical technology, and the early results suggest the speed, safety and effectiveness of the nPulse Surgical Cardiac Clamps efficient workflow has the potential to significantly expand the use of cardiac surgical ablation for patients suffering from atrial fibrillation."
• Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences: "Pulse Biosciences is the first company to bring PFA into the cardiac surgical field for the treatment of atrial fibrillation."
• Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences: "We believe our novel and proprietary nonthermal nPulse technology offers significant advantages in safety, as demonstrated across our multiple clinical applications, as well as efficacy, and speed compared to traditional thermal ablation methods like radiofrequency."

Industry Context

Pulse Biosciences is pioneering the application of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) energy with the nPulse Cardiac Surgical System for the treatment of atrial fibrillation. This represents a significant advancement in the cardiac surgical field, offering a non-thermal alternative to traditional thermal ablation methods like radiofrequency, with the potential to enhance safety, efficacy, and procedural speed for AF patients.

Comparison to Industry Standards

• nPulse technology offers significant advantages in safety, efficacy, and speed compared to traditional thermal ablation methods like radiofrequency.
• The nPulse Cardiac Surgical System's efficient workflow and rapid ablation times suggest it could significantly expand the use of cardiac surgical ablation for atrial fibrillation patients, potentially surpassing the adoption rates of current surgical ablation approaches.

Related Party Transactions

• Dr. Bart van Putte, one of the investigators in the feasibility study, serves as a consultant to Pulse Biosciences.

Stakeholder Impact

• Shareholders: The highly positive clinical results are likely to increase investor confidence and could lead to positive share price movement.
• Patients: The nPulse Cardiac Surgical System offers a potentially safer, more effective, and faster treatment option for atrial fibrillation, with reduced risks of complications such as esophageal or phrenic nerve damage.
• Healthcare Providers (Surgeons): The system provides an efficient workflow and rapid ablation times, which could improve surgical outcomes and procedural efficiency.

Next Steps

• Initiate an IDE study this year to clinically validate the nPulse Cardiac Surgical System.
• Continue collaboration with leading physicians.
• Work towards commercial approval and broader patient access for the nPulse Cardiac Surgical System.

Key Dates

Recommendation

The clinical data presented is exceptionally strong, demonstrating 100% acute success for posterior box isolations and a 94% durable PVI success rate at three months, coupled with a rapid ablation time and a pristine safety profile (no esophageal or phrenic nerve damage, no major adverse events). This positions Pulse Biosciences' nPulse Cardiac Surgical System as a potentially transformative technology in the large and growing atrial fibrillation market, offering significant advantages over traditional thermal ablation methods. The initiation of an IDE study this year further de-risks the path to commercialization. These results are highly indicative of future success and represent a significant positive catalyst for the company.

Keywords

Pulse Biosciences, nPulse, Cardiac Surgical System, Atrial Fibrillation, AF, Pulsed Field Ablation, PFA, Nanosecond Pulsed Field Ablation, nsPFA, clinical study, feasibility study, cardiac ablation, pulmonary vein isolation, PVI, posterior box isolation, medical device, bioelectric medicine